8-K Announcements
6Material company update
Apr 7, 2026·SEC
Material company update
Feb 27, 2026·SEC
Material company update
Feb 26, 2026·SEC
Ginkgo Bioworks Holdings, Inc.(DNA)Earnings, Financials & Key Ratios
DNA•NYSE
$10.08
$489M mkt cap·Price updated May 6, 2026
AboutGinkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Show more
- Revenue$170M-25.1%
- EBITDA-$315M+36.5%
- Net Income-$313M+42.8%
- EPS (Diluted)-5.64+46.5%
- Gross Margin81.48%-1.9%
- EBITDA Margin-185.29%+15.3%
- Operating Margin-185.29%+24.8%
- Net Margin-183.81%+23.7%
- ROE-51.08%+15.3%
- ROIC-34.25%+58.6%
- Debt/Equity0.82+25.5%
DNA Key Insights
Ginkgo Bioworks Holdings, Inc. (DNA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 17.3%
- ✓Trading at only 1.1x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DNA Price & Volume
Ginkgo Bioworks Holdings, Inc. (DNA) stock price & volume — 10-year historical chart
Loading chart...
DNA Growth Metrics
Ginkgo Bioworks Holdings, Inc. (DNA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years17.29%
3 Years-29.11%
TTM-25.06%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM42.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM47.1%
Return on Capital
10 Years-56%
5 Years-71.87%
3 Years-37.53%
Last Year-27.49%
DNA Recent Earnings
Ginkgo Bioworks Holdings, Inc. (DNA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 9/12 qtrs (75%)
Q1 2026Latest
Feb 26, 2026EPS
$1.42
Est $1.80
+21.1%
Revenue
$33M
Est $37M
-11.0%
Q4 2025
Nov 6, 2025EPS
$1.45
Est $1.24
-16.9%
Revenue
$39M
Est $38M
+3.4%
Q3 2025
Aug 7, 2025EPS
$1.10
Est $1.44
+23.6%
Revenue
$50M
Est $39M
+27.4%
Q2 2025
May 6, 2025EPS
$1.58
Est $1.23
-28.5%
Revenue
$48M
Est $42M
+16.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 26, 2026 | $1.42vs $1.80+21.1% | $33Mvs $37M-11.0% |
| Q4 2025 | Nov 6, 2025 | $1.45vs $1.24-16.9% | $39Mvs $38M+3.4% |
| Q3 2025 | Aug 7, 2025 | $1.10vs $1.44+23.6% | $50Mvs $39M+27.4% |
| Q2 2025 | May 6, 2025 | $1.58vs $1.23-28.5% | $48Mvs $42M+16.2% |
Based on last 12 quarters of dataView full earnings history →
DNA Peer Comparison
Ginkgo Bioworks Holdings, Inc. (DNA) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 TWST | 3.71B | 59.53 | -45.79 | 20.32% | -19.85% | -17.46% | 0.29 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 FATE | 264.17M | 2.29 | -1.99 | -51.24% | -20.51% | -65.79% | 0.38 |
Compare DNA vs Peers
Ginkgo Bioworks Holdings, Inc. (DNA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DNA Income Statement
Ginkgo Bioworks Holdings, Inc. (DNA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 54.18M | 76.66M | 313.84M | 477.71M | 251.46M | 227.04M | 170.16M |
| Revenue Growth % | - | 41.48% | 309.4% | 52.21% | -47.36% | -9.71% | -25.06% |
| Cost of Goods Sold | 0 | 15.61M | 129.69M | 204.22M | 54.01M | 38.55M | 31.52M |
| COGS % of Revenue | - | 20.36% | 41.32% | 42.75% | 21.48% | 16.98% | 18.52% |
| Gross Profit | 54.18M▲ 0% | 61.05M▲ 12.7% | 184.15M▲ 201.7% | 273.49M▲ 48.5% | 197.45M▼ 27.8% | 188.49M▼ 4.5% | 138.63M▼ 26.5% |
| Gross Margin % | 100% | 79.64% | 58.68% | 57.25% | 78.52% | 83.02% | 81.48% |
| Gross Profit Growth % | - | 12.66% | 201.65% | 48.52% | -27.8% | -4.54% | -26.45% |
| Operating Expenses | 125.78M | 198.07M | 2.01B | 2.48B | 1.06B | 748.25M | 453.91M |
| OpEx % of Revenue | 232.14% | 258.39% | 641.29% | 519.66% | 422.28% | 329.56% | 266.76% |
| Selling, General & Admin | 29.48M | 38.31M | 862.95M | 1.43B | 385.02M | 246.16M | 183.29M |
| SG&A % of Revenue | 54.41% | 49.97% | 274.97% | 299.31% | 153.12% | 108.42% | 107.72% |
| Research & Development | 96.3M | 159.77M | 1.15B | 1.05B | 580.62M | 424.06M | 243.77M |
| R&D % of Revenue | 177.73% | 208.42% | 366.32% | 220.35% | 230.9% | 186.78% | 143.27% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 96.21M | 78.03M | 26.85M |
| Operating Income | -71.6M▲ 0% | -137.03M▼ 91.4% | -1.83B▼ 1234.4% | -2.21B▼ 20.8% | -864.41M▲ 60.9% | -559.76M▲ 35.2% | -315.28M▲ 43.7% |
| Operating Margin % | -132.14% | -178.75% | -582.62% | -462.41% | -343.76% | -246.54% | -185.29% |
| Operating Income Growth % | - | -91.38% | -1234.38% | -20.81% | 60.87% | 35.24% | 43.68% |
| EBITDA | -60.84M | -123.16M | -1.8B | -2.15B | -792.85M | -496.74M | -315.28M |
| EBITDA Margin % | -112.29% | -160.67% | -573.35% | -449.51% | -315.31% | -218.79% | -185.29% |
| EBITDA Growth % | - | -102.43% | -1360.98% | -19.34% | 63.08% | 37.35% | 36.53% |
| D&A (Non-Cash Add-back) | 10.76M | 13.86M | 29.08M | 61.63M | 71.55M | 63.02M | 0 |
| EBIT | -117.41M | -122.45M | -1.84B | -2.12B | -892.85M | -547.41M | 0 |
| Net Interest Income | 3.33M | 197K | -1.54M | 20.16M | 57.12M | 38.52M | 0 |
| Interest Income | 5.76M | 2.58M | 837K | 20.26M | 57.22M | 38.61M | 22.62M |
| Interest Expense | 2.42M | 2.38M | 2.37M | 106K | 93K | 94K | 0 |
| Other Income/Expense | -48.24M | 12.19M | -9.65M | 87.55M | -28.53M | 12.25M | 1.68M |
| Pretax Income | -119.83M▲ 0% | -124.83M▼ 4.2% | -1.84B▼ 1372.5% | -2.12B▼ 15.4% | -892.94M▲ 57.9% | -547.51M▲ 38.7% | -313.6M▲ 42.7% |
| Pretax Margin % | -221.16% | -162.85% | -585.69% | -444.08% | -355.11% | -241.15% | -184.3% |
| Income Tax | 22K | 1.89M | -1.48M | -15.03M | -71K | -479K | -837K |
| Effective Tax Rate % | -0.02% | -1.51% | 0.08% | 0.71% | 0.01% | 0.09% | 0.27% |
| Net Income | -119.33M▲ 0% | -126.61M▼ 6.1% | -1.83B▼ 1345.4% | -2.1B▼ 15.0% | -892.87M▲ 57.6% | -547.03M▲ 38.7% | -312.76M▲ 42.8% |
| Net Margin % | -220.23% | -165.16% | -583.12% | -440.63% | -355.08% | -240.94% | -183.81% |
| Net Income Growth % | - | -6.1% | -1345.43% | -15.02% | 57.58% | 38.73% | 42.83% |
| Net Income (Continuing) | -119.86M | -126.72M | -1.84B | -2.11B | -892.87M | -547.03M | -312.76M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 8.79M | 8.68M | 62.01M | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.15▲ 0% | -4.00▲ 3.6% | -55.53▼ 1288.3% | -50.20▲ 9.6% | -18.40▲ 63.3% | -10.54▲ 42.7% | -5.64▲ 46.5% |
| EPS Growth % | - | 3.61% | -1288.25% | 9.6% | 63.35% | 42.72% | 46.49% |
| EPS (Basic) | -4.15 | -3.97 | -53.83 | -50.15 | -18.37 | -10.54 | -5.64 |
| Diluted Shares Outstanding | 28.73M | 31.87M | 34.01M | 42M | 48.61M | 51.89M | 55.46M |
| Basic Shares Outstanding | 28.73M | 31.65M | 32.95M | 41.93M | 48.53M | 51.89M | 55.46M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
DNA Balance Sheet
Ginkgo Bioworks Holdings, Inc. (DNA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 511.93M | 426.54M | 1.72B | 1.45B | 1B | 602.74M | 471.84M |
| Cash & Short-Term Investments | 495.29M | 380.8M | 1.55B | 1.32B | 944.07M | 561.57M | 422.62M |
| Cash Only | 495.29M | 380.8M | 1.55B | 1.32B | 944.07M | 561.57M | 167.2M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 255.42M |
| Accounts Receivable | 7.68M | 21.91M | 149.9M | 84.03M | 17.9M | 22.44M | 24.03M |
| Days Sales Outstanding | 51.72 | 104.3 | 174.34 | 64.2 | 25.98 | 36.08 | 51.54 |
| Inventory | 0 | 9.27M | 3.36M | 4.36M | 46K | 0 | 0 |
| Days Inventory Outstanding | - | 216.79 | 9.46 | 7.8 | 0.31 | - | - |
| Other Current Assets | 6.41M | 3.71M | 698K | 8.71M | 18.99M | 18.73M | 25.19M |
| Total Non-Current Assets | 185.39M | 248.61M | 347.94M | 1.09B | 663.59M | 774.71M | 647.86M |
| Property, Plant & Equipment | 63.13M | 121.44M | 145.77M | 718.79M | 394.99M | 598.15M | 528.7M |
| Fixed Asset Turnover | 0.86x | 0.63x | 2.15x | 0.66x | 0.64x | 0.38x | 0.32x |
| Goodwill | 1.86M | 1.86M | 21.31M | 60.21M | 49.24M | 0 | 0 |
| Intangible Assets | 3.84M | 3.29M | 21.64M | 111.04M | 82.74M | 72.51M | 56.92M |
| Long-Term Investments | 107.25M | 103.12M | 115.23M | 111.79M | 77.91M | 48.7M | 15.07M |
| Other Non-Current Assets | 9.31M | 18.9M | 43.99M | 87.41M | 58.71M | 55.34M | 47.17M |
| Total Assets | 697.32M▲ 0% | 675.15M▼ 3.2% | 2.07B▲ 206.7% | 2.54B▲ 22.6% | 1.67B▼ 34.4% | 1.38B▼ 17.3% | 1.12B▼ 18.7% |
| Asset Turnover | 0.08x | 0.11x | 0.15x | 0.19x | 0.15x | 0.16x | 0.15x |
| Asset Growth % | - | -3.18% | 206.74% | 22.61% | -34.42% | -17.29% | -18.71% |
| Total Current Liabilities | 40.07M | 73.22M | 134.76M | 172.96M | 163.86M | 107.27M | 95.97M |
| Accounts Payable | 2.44M | 13.89M | 8.19M | 10.45M | 9.32M | 14.17M | 10.57M |
| Days Payables Outstanding | - | 324.83 | 23.05 | 18.68 | 63.01 | 134.16 | 122.35 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 33.24M | 47.82M | 48.49M | 30.6M | 18.95M |
| Other Current Liabilities | 23.44M | 41.12M | 40.31M | 52.51M | 54.38M | 26.62M | 77.02M |
| Current Ratio | 12.77x | 5.83x | 12.79x | 8.38x | 6.11x | 5.62x | 4.92x |
| Quick Ratio | 12.77x | 5.70x | 12.76x | 8.36x | 6.11x | 5.62x | 4.92x |
| Cash Conversion Cycle | - | -3.74 | 160.75 | 53.32 | -36.72 | - | - |
| Total Non-Current Liabilities | 155.39M | 131.88M | 368.85M | 630.08M | 404.33M | 554.13M | 515.14M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 417.08M |
| Capital Lease Obligations | 16.77M | 16.52M | 22.28M | 413.26M | 221.84M | 438.77M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 138.62M | 115.36M | 190.58M | 42.06M | 24.43M | 16.58M | 98.06M |
| Total Liabilities | 195.47M | 205.1M | 503.61M | 803.04M | 568.19M | 661.39M | 611.11M |
| Total Debt | 17.36M | 17M | 23.03M | 442.59M | 239.31M | 467.73M | 417.08M |
| Net Debt | -477.92M | -363.8M | -1.53B | -873.2M | -704.76M | -93.84M | 249.88M |
| Debt / Equity | 0.03x | 0.04x | 0.01x | 0.25x | 0.22x | 0.65x | 0.82x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -29.57x | -57.45x | -770.53x | -20839.17x | -9294.69x | -5954.86x | - |
| Total Equity | 501.85M▲ 0% | 470.05M▼ 6.3% | 1.57B▲ 233.4% | 1.74B▲ 10.8% | 1.1B▼ 36.8% | 716.06M▼ 34.7% | 508.59M▼ 29.0% |
| Equity Growth % | - | -6.34% | 233.45% | 10.78% | -36.81% | -34.73% | -28.97% |
| Book Value per Share | 17.47 | 14.75 | 46.09 | 41.34 | 22.57 | 13.80 | 9.17 |
| Total Shareholders' Equity | 493.06M | 461.38M | 1.51B | 1.74B | 1.1B | 716.06M | 508.59M |
| Common Stock | 79K | 129K | 161K | 190K | 5K | 5K | 6K |
| Retained Earnings | -341.27M | -467.88M | -2.3B | -4.4B | -5.29B | -5.84B | -6.15B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -1.72M | -2.63M | 1.48M | -1.81M | 1.85M |
| Minority Interest | 8.79M | 8.68M | 62.01M | 0 | 0 | 0 | 0 |
DNA Cash Flow Statement
Ginkgo Bioworks Holdings, Inc. (DNA) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -44.66M | -135.83M | -253.82M | -252.2M | -295.5M | -319.58M | -171.06M |
| Operating CF Margin % | -82.43% | -177.19% | -80.88% | -52.79% | -117.52% | -140.76% | -100.53% |
| Operating CF Growth % | - | -204.12% | -86.86% | 0.64% | -17.17% | -8.15% | 46.47% |
| Net Income | -119.86M | -126.72M | -1.84B | -2.11B | -892.87M | -547.03M | -312.76M |
| Depreciation & Amortization | 10.76M | 13.86M | 29.08M | 42.55M | 71.55M | 63.02M | 58.99M |
| Stock-Based Compensation | 771K | 476K | 1.61B | 1.93B | 229.88M | 112.34M | 81.55M |
| Deferred Taxes | 54.73M | 0 | 30.21M | -14.61M | -801K | -936K | -1.36M |
| Other Non-Cash Items | -1.64M | 3.07M | -20.95M | -67.4M | 266.89M | 142.69M | 2.53M |
| Working Capital Changes | 10.58M | -26.52M | -61.54M | -37.01M | 29.84M | -89.67M | 0 |
| Change in Receivables | -1.84M | -14.23M | -114.09M | 55.02M | 50.07M | -4.72M | -1.47M |
| Change in Inventory | -2.22M | -2.74M | -626K | 164K | 0 | 0 | 0 |
| Change in Payables | 664K | 7.02M | -2.25M | -10.84M | -1.18M | 4.77M | -2.99M |
| Cash from Investing | -74.6M | -67.12M | -73.26M | -67.39M | -80.69M | -62.24M | -240.29M |
| Capital Expenditures | -22.22M | -57.82M | -56.52M | -52.27M | -40.8M | -62.54M | -7.67M |
| CapEx % of Revenue | 41.01% | 75.43% | 18.01% | 10.94% | 16.23% | 27.55% | 4.5% |
| Acquisitions | 0 | 0 | -12.04M | 26.65M | -38.55M | -5.4M | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -2.25M | -9.3M | 304K | -38.08M | -1.34M | 1.19M | 624K |
| Cash from Financing | 410.38M | 90.32M | 1.53B | 95.34M | -3.22M | -1.74M | 0 |
| Debt Issued (Net) | 198.6M | -748K | -1.12M | -1.24M | -1.29M | -897K | 0 |
| Equity Issued (Net) | 1000K | 1000K | -1000K | 1000K | -487K | 80K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -408K | 0 | -25M | 0 | -23K | 0 | 0 |
| Other Financing | 7K | 26K | 1.56B | -2.73M | -1.43M | -922K | 0 |
| Net Change in Cash | 291.12M▲ 0% | -112.63M▼ 138.7% | 1.21B▲ 1171.7% | -223.35M▼ 118.5% | -380M▼ 70.1% | -383.84M▼ 1.0% | 0▲ 100.0% |
| Free Cash Flow | -66.88M▲ 0% | -193.65M▼ 189.5% | -310.34M▼ 60.3% | -304.47M▲ 1.9% | -336.3M▼ 10.5% | -382.13M▼ 13.6% | -178.72M▲ 53.2% |
| FCF Margin % | -123.44% | -252.62% | -98.89% | -63.74% | -133.74% | -168.31% | -105.04% |
| FCF Growth % | - | -189.54% | -60.26% | 1.89% | -10.45% | -13.63% | 53.23% |
| FCF per Share | -2.33 | -6.08 | -9.13 | -7.25 | -6.92 | -7.36 | -3.22 |
| FCF Conversion (FCF/Net Income) | 0.37x | 1.07x | 0.14x | 0.12x | 0.33x | 0.58x | 0.55x |
| Interest Paid | 2.35M | 2.57M | 2.37M | 92K | 83K | 32K | 0 |
| Taxes Paid | 31K | 0 | 61K | 0 | 670K | 894K | 0 |
DNA Key Ratios
Ginkgo Bioworks Holdings, Inc. (DNA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -23.78% | -26.05% | -179.64% | -127.43% | -63.02% | -60.34% | -51.08% |
| Return on Invested Capital (ROIC) | -224.39% | -157.88% | -1870.12% | -366.74% | -103.28% | -82.75% | -34.25% |
| Gross Margin | 100% | 79.64% | 58.68% | 57.25% | 78.52% | 83.02% | 81.48% |
| Net Margin | -220.23% | -165.16% | -583.12% | -440.63% | -355.08% | -240.94% | -183.81% |
| Debt / Equity | 0.03x | 0.04x | 0.01x | 0.25x | 0.22x | 0.65x | 0.82x |
| Interest Coverage | -29.57x | -57.45x | -770.53x | -20839.17x | -9294.69x | -5954.86x | - |
| FCF Conversion | 0.37x | 1.07x | 0.14x | 0.12x | 0.33x | 0.58x | 0.55x |
| Revenue Growth | - | 41.48% | 309.4% | 52.21% | -47.36% | -9.71% | -25.06% |
DNA SEC Filings & Documents
Ginkgo Bioworks Holdings, Inc. (DNA) SEC filings — annual & quarterly reports (10-K, 10-Q)
DNA Frequently Asked Questions
Ginkgo Bioworks Holdings, Inc. (DNA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ginkgo Bioworks Holdings, Inc. (DNA) reported $170.2M in revenue for fiscal year 2025. This represents a 214% increase from $54.2M in 2019.
Ginkgo Bioworks Holdings, Inc. (DNA) saw revenue decline by 25.1% over the past year.
Ginkgo Bioworks Holdings, Inc. (DNA) reported a net loss of $312.8M for fiscal year 2025.
Dividend & Returns
Ginkgo Bioworks Holdings, Inc. (DNA) has a return on equity (ROE) of -51.1%. Negative ROE indicates the company is unprofitable.
Ginkgo Bioworks Holdings, Inc. (DNA) had negative free cash flow of $194.0M in fiscal year 2025, likely due to heavy capital investments.
Explore More DNA
Ginkgo Bioworks Holdings, Inc. (DNA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates